- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Luvox® | U-23000
fluvoxamine is an approved drug (FDA (1994))
Compound class: Synthetic organic
Comment: Fluvoxamine is an antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) drug group.
Marketed formulations may contain fluvoxamine maleate (PubChem CID 9560989).
SARS-CoV-2 and COVID-19: Evidence that is emerging from randomised, placebo-controlled clinical trials  suggests that fluvoxamine may offer potential as a therapuetic for non-hospitalised COVID-19 patients. Multiple fluvoxamine mechanisms of action may be at play , and much remains to clarified about the patients who would benefit most, efficacy in infections with different SARS-CoV-2 variants, and whether fluvoxamine's effect occurs in addition to the benefit demonstrated by other therapies.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: fluvoxamine
|No information available.|
|Summary of Clinical Use|
|Used to treat major depressive episodes and obsessive compulsive disorder (OCD).
SARS-CoV-2 and COVID-19: The potential of fluvoxamine has been evaluated in symptomatic COVID-19 outpatients, with preliminary signs of benefit . Fluvoxamine is propsed to modulate the effects of peripheral serotonin on systemic inflammation  in COVID-19 . It may also have a beneficial effect via regulation of platelet-derived serotonin's role in recruiting innate immune cells (that express 5-HT receptors) to sites of inflammation .
|Mechanism Of Action and Pharmacodynamic Effects|
|SSRIs increase serotonin levels at post-synaptic sites by inhibiting the pre-synaptic transporter, SERT (SLC6A4), normally involved in serotonin re-uptake. This enhances serotonergic neurotransmission with the clinical outcomes being improved mood and decreased anxiety. See the DrugBank link for further details.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04342663||A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection||Phase 2 Interventional||Washington University School of Medicine||The preliminary signs of efficacy observed in this study (reduction in chance of clinical deterioration over 15 days in treatment arm) would need to be followed up in larger scale RCTs with a longer follow-up timescale.||5|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)